Floatz logo

ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4)

Metastatic Urothelial Carcinoma

Vasgene Therapeutics, Incantibody_drug_conjugatePhase 2/3Active
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
60/ 100
Competitive Position
89/ 100

Competitive context

166 Active assets in the Metastatic Urothelial Carcinoma cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Beijing Biotech
Phase 3BB
Durvalumab
Alliance for Clinical Trials in Oncology
Phase 3BB
Pembrolizumab
Sutro Biopharma, Inc.
Phase 3BB
CIS-DIAMMINEDICHLOROPLATINUM II
Nagoya University
Phase 3BB
IMMUNOGLOBULIN G1, ANTI-(HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR TYPE VEGFR-2 EXTRACELLULAR DOMAIN) (HUMAN MONOCLONAL IMC-1121B .GAMMA.-CHAIN), DISULPHIDE WITH HUMAN MONOCLONAL IMC-1121B .KAPPA.-CHAIN, DIMER
Eli Lilly and Company
Phase 3BB

View all 50 →

Same molecule, other indications

ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4) is also rated in:

urinary bladder neoplasmDormant
BB
Indicative ·
68 / 100
View asset →
ureter neoplasmDormant
BB
Indicative ·
68 / 100
View asset →
renal pelvis/ureter urothelial carcinomaDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →